Literature DB >> 15649673

A cohort study linked increased mortality in patients treated surgically for Dupuytren's contracture.

Stephan Wilbrand1, Anders Ekbom, Bengt Gerdin.   

Abstract

OBJECTIVE: Dupuytren's contracture (DC) is a fibromatous disease of the palmar fascia of unknown etiology. The objective of this study was to assess whether individuals treated for DC exhibited an altered standardized mortality ratio. STUDY DESIGN AND
SETTING: A total of 16,517 patients operated on for DC between 1965 and 1995 were identified by the Swedish Inpatient Register. For the 7,579 patients who had died during that period, cause of death was obtained from the Swedish Death Register.
RESULTS: There was an overall increased mortality (standardized mortality ratio [SMR]=1.06), inversely related to age and significant for both sexes, in patients under 70 years of age. The risk estimate was highest for endocrine diseases (highest value in patients 40-49 years of age at surgery; SMR=2.82), gastrointestinal diseases (highest value in those 40-49 years of age at surgery; SMR=2.69), accidents (highest value in those 30-39 years of age at surgery; SMR=2.40), and respiratory diseases (highest value in those 50-59 years of age at surgery; SMR=1.61). There was also an increased SMR for cardiovascular diseases in patients 40-59 years of age more than 10 years after surgery (highest value in those 40-49 years of age at surgery; SMR=1.65).
CONCLUSION: The most probable mechanism for the increased mortality is related to smoking and other lifestyle factors.

Entities:  

Mesh:

Year:  2005        PMID: 15649673     DOI: 10.1016/j.jclinepi.2004.05.007

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  1 in total

1.  Dupuytren's Disease Predicts Increased All-Cause and Cancer-Specific Mortality: Analysis of a Large Cohort from the U.K. Clinical Practice Research Datalink.

Authors:  Rachel Yi Ling Kuo; Michael Ng; Daniel Prieto-Alhambra; Dominic Furniss
Journal:  Plast Reconstr Surg       Date:  2020-03       Impact factor: 5.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.